What is a stock summary page? Click here for an overview.
Business Description
Avalo Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US15671L1098
Description
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 236.88 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.23 | |||||
| Beneish M-Score | 12.66 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -92.7 | |||||
| 3-Year EBITDA Growth Rate | 86.8 | |||||
| 3-Year EPS without NRI Growth Rate | 79.3 | |||||
| 3-Year FCF Growth Rate | 85.1 | |||||
| 3-Year Book Growth Rate | -72.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 39.16 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.57 | |||||
| 9-Day RSI | 50.27 | |||||
| 14-Day RSI | 50.36 | |||||
| 3-1 Month Momentum % | -8.06 | |||||
| 6-1 Month Momentum % | -16.92 | |||||
| 12-1 Month Momentum % | 65.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.96 | |||||
| Quick Ratio | 19.96 | |||||
| Cash Ratio | 19.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -545.7 | |||||
| Shareholder Yield % | -124.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 182.54 | |||||
| Operating Margin % | -9268.25 | |||||
| Net Margin % | -7965.76 | |||||
| FCF Margin % | -11123.81 | |||||
| ROE % | -375.96 | |||||
| ROA % | -34.97 | |||||
| ROIC % | -48.74 | |||||
| 3-Year ROIIC % | -544.4 | |||||
| ROC (Joel Greenblatt) % | -2252.29 | |||||
| ROCE % | -162.62 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 200.23 | |||||
| PB Ratio | 0.6 | |||||
| Price-to-Tangible-Book | 0.65 | |||||
| EV-to-EBIT | 0.79 | |||||
| EV-to-EBITDA | 0.79 | |||||
| EV-to-Revenue | -122.61 | |||||
| EV-to-Forward-Revenue | 0.3 | |||||
| EV-to-FCF | -0.1 | |||||
| Price-to-GF-Value | 84.78 | |||||
| Price-to-Net-Current-Asset-Value | 0.66 | |||||
| Price-to-Net-Cash | 0.69 | |||||
| Earnings Yield (Greenblatt) % | 126.58 | |||||
| FCF Yield % | -61.23 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AVTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Avalo Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.441 | ||
| EPS (TTM) ($) | -3523.979 | ||
| Beta | 0.23 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 408.72 | ||
| 14-Day RSI | 50.36 | ||
| 14-Day ATR ($) | 0.809342 | ||
| 20-Day SMA ($) | 7.4065 | ||
| 12-1 Month Momentum % | 65.98 | ||
| 52-Week Range ($) | 4.6 - 34.46 | ||
| Shares Outstanding (Mil) | 10.5 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Avalo Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Avalo Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Avalo Therapeutics Inc Frequently Asked Questions
What is Avalo Therapeutics Inc(AVTX)'s stock price today?
The current price of AVTX is $7.63. The 52 week high of AVTX is $34.46 and 52 week low is $4.60.
When is next earnings date of Avalo Therapeutics Inc(AVTX)?
The next earnings date of Avalo Therapeutics Inc(AVTX) is 2025-05-13 Est..
Does Avalo Therapeutics Inc(AVTX) pay dividends? If so, how much?
Avalo Therapeutics Inc(AVTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers